Portfolio company
Araris Biotech
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops antibody-drug conjugate linker technology and targeted cancer therapies for pharmaceutical partners and patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
araris
This company develops antibody-drug conjugate linker technology to create targeted cancer therapies for the pharmaceutical and biotechnology industries.
Mablink Bioscience
This biotechnology firm develops antibody-drug conjugates for pharmaceutical companies to treat cancer using a proprietary hydrophilic linker platform.
Adcytherix
This biopharmaceutical company develops novel antibody-drug conjugates to treat various forms of cancer for patients with high unmet clinical needs.
Angiex
This company develops antibody-drug conjugates for clinicians and pharmaceutical partners to treat solid cancers and vascular diseases.
Adcendo
This clinical-stage biotechnology company develops antibody-drug conjugates to treat patients with various types of cancer and high unmet medical needs.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
Pinot Bio
The company develops antibody-drug conjugate platforms and targeted anticancer therapeutics for pharmaceutical firms and clinical-stage biotechnology partners.
Promatix
Promatix develops antibody-drug conjugates for cancer treatment using a proprietary multi-omics platform to identify and target specific tumour markers.